Latest Sales Growth News

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

James Hardie Industries releases its 2026 AGM materials, highlighting a $4.8 billion sales year boosted by AZEK acquisition, board renewals, and a revamped executive pay structure.

Biome Australia has posted a 30% increase in FY26 sales revenue to $23.9 million, driven by strong domestic demand and strategic moves into onshore manufacturing and international markets.

Burger Fuel Group posted a 92% surge in net profit to NZ$1.97 million for FY26, driven by steady system sales growth, a one-off store sale gain, and reduced legal expenses, while geopolitical instability in the Middle East weighs on international sales.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

CONNEQT Health Limited is offering eligible shareholders a share purchase plan to raise up to $0.5 million at a 24.3% discount, aiming to fund its next growth phase in vascular health technology.

Collins Foods delivered record FY26 revenue and underlying profit, declaring a 15c fully franked final dividend while exiting Taco Bell to sharpen focus on KFC expansion in Australia and Europe.

Cooks Coffee lifted UK and Ireland store sales 22.8% to NZ$95.8 million in FY26, with EBITDA up 14% to NZ$1.39 million. Despite operational growth and debt reduction, net liabilities and liquidity pressures raise material going concern doubts.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.

Baby Bunting anticipates FY26 pro forma NPAT between $16 million and $17 million, marking a 32% to 40% increase from FY25, despite weaker sales in the fourth quarter. The retailer’s Store of the Future refurbishments and online channels continue to drive growth amid a challenging consumer backdrop.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.